NecstGen and Astraveus explore benchtop CAR-T manufacturing


NecstGen has partnered with Paris-based biotech Astraveus to evaluate the Lakhesys™ Benchtop Cell Factory™, a microfluidic-based platform aiming to simplify and scale CAR-T production. The collaboration will test the system’s potential to reduce cost, footprint, and manual steps in a GMP setting.

The partnership strengthens NecstGen’s role in advancing cell therapy manufacturing and highlights Astraveus’ vision for decentralized, efficient production.

Read more: https://necstgen.com/necstgen-and-astraveus-collaborate-to-evaluate-benchtop-cell-factory-technology-for-scalable-car-t-manufacturing/


  • LUMC opens dedicated CAR-T department

    Leiden University Medical Center (LUMC) has opened a dedicated department for CAR-T cell therapy, bringing care, research and expertise in this rapidly developing field together in one place. The new department, officially opened on 24 September, marks another step in…

  • VarmX recognised with two prestigious industry award nominations

    Leiden-based biotech company VarmX has received two industry award nominations recognising its scientific approach and strategic partnership with CSL. VarmX has been shortlisted for the 2026 Prix Galien USA “Best Startup” Award, which recognises early-stage companies developing novel therapeutic approaches.…